Induction of immune tolerance to FIX by intramuscular AAV gene transfer is independent of the activation status of dendritic cells

Blood

Volumn 115, Issue 3, 2010, Pages 500-509

  Bharadwaj, Arpita S ^a   Kelly, Meagan ^a   Kim, Dongsoo ^a   Chao, Hengjun ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 9; CD40 ANTIGEN; LIPOPOLYSACCHARIDE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DENDRITIC CELL; HEMOPHILIA; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; ADENO ASSOCIATED VIRUS; ANIMAL; BAGG ALBINO MOUSE; C3H MOUSE; C57BL MOUSE; CELL CULTURE; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; PRODUCTIVITY; TIME; VALIDATION STUDY;

ANIMALS; CELLS, CULTURED; DENDRITIC CELLS; DEPENDOVIRUS; EFFICIENCY; FACTOR IX; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNE TOLERANCE; INJECTIONS, INTRAMUSCULAR; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; TIME FACTORS; TRANSDUCTION, GENETIC;

EID: 77449143240     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-08-239509     Document Type: Article

References (27)

1. Hackett NR, Kaminsky SM, Sondhi D, Crystal RG. Antivector and antitransgene host responses in gene therapy. Curr Opin Mol Ther. 2000;2:376-382.
2. Brown BD, Lillicrap D. Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy. Blood. 2002;100:1133-1140.
3. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med. 2006;12:342-347.
4. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003; 80:148-158.
5. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045.
6. Diebold SS. Determination of T-cell fate by dendritic cells. Immunol Cell Biol. 2008;86:389-397.
7. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001;106:255-258.
8. Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol. 2001;2:585-589.
9. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685-711.
10. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood. 2006;108:1435-1440.
11. McCaffrey AP, Fawcett P, Nakai H, et al. The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol Ther. 2008;16:931-941.
12. Stilwell JL, Samulski RJ. Role of viral vectors and virion shells in cellular gene expression. Mol Ther. 2004;9:337-346.
13. Cohn EF, Zhuo J, Kelly ME, Chao HJ. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer. J Thromb Haemost. 2007;5:1227-1236.
14. Chao H, Monahan PE, Liu Y, Samulski RJ, Walsh CE. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther. 2001;4:217-222.
15. Kelly ME, Zhuo J, Bharadwaj AS, Chao H. Induction of immune tolerance to FIX following muscular AAV gene transfer is AAV-dose/FIX-level dependent. Mol Ther. 2009;17:857-863.
16. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A. 1995;92:1401-1405.
17. Ge Y, Powell S, Van Roey M, McArthur JG. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood. 2001; 97:3733-3737.
18. Zhang TP, Jin DY, Wardrop RM III, et al. Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice. Gene Ther. 2007;14:429-440.
19. Fields PA, Arruda VR, Armstrong E, et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther. 2001;4:201-210.
20. Herzog RW, Fields PA, Arruda VR, et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther. 2002;13:1281-1291.
21. Pulendran B, Kumar P, CutlerCW, Mohamadzadeh M, Van Dyke T, Banchereau J. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J Immunol. 2001;167: 5067-5076.
22. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004;22: 307-328.
23. Maxwell JR, Campbell JD, Kim CH, Vella AT. CD40 activation boosts T cell immunity in vivo by enhancing T cell clonal expansion and delaying peripheral T cell deletion. J Immunol. 1999;162: 2024-2034.
24. Fields PA, Armstrong E, Hagstrom JN, et al. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice. Gene Ther. 2001;8:354-361.
25. Tulone C, Tsang J, Prokopowicz Z, Grosvenor N, Chain B. Natural cathepsin E deficiency in the immune system of C57BL/6J mice. Immunogenetics. 2007;59:927-935.
26. Tenenbaum L, Lehtonen E, Monahan PE. Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther. 2003;3:545-565.
27. Follenzi A, Battaglia M, Lombardo A, Annoni A, Roncarolo MG, Naldini L. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood. 2004;103:3700-3709.